Pathogenesis of Nonalcoholic Steatohepatitis: Interactions between Liver Parenchymal and Nonparenchymal Cells

BioMed Research International

Volumn 2016, Issue , 2016, Pages

  Magee, Nancy ^a   Zou, An ^a   Zhang, Yuxia ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CRYOPYRIN; PIOGLITAZONE; PROBIOTIC AGENT;

DISEASE COURSE; ENDOPLASMIC RETICULUM STRESS; EPIGENETICS; GENETIC REGULATION; HUMAN; IMMUNITY; INFLAMMATION; LIPOTOXICITY; LIVER CELL; LIVER CELL DAMAGE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; DRINKING BEHAVIOR; FIBROSIS; IMMUNOLOGY; LIVER; METABOLIC SYNDROME X; PARENCHYMA; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALCOHOL DRINKING; ENDOPLASMIC RETICULUM STRESS; FIBROSIS; HEPATOCYTES; HUMANS; LIVER; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; PARENCHYMAL TISSUE;

EID: 84994620491     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2016/5170402     Document Type: Review

References (130)

1. I. A. Kirpich, L. N. Gobejishvili, M. Bon Homme et al., "Integrated hepatic transcriptome and proteome analysis of mice with high-fat diet-induced nonalcoholic fatty liver disease, " The Journal of Nutritional Biochemistry, vol. 22, no. 1, pp. 38-45, 2011.
2. V. Uppal, S. Mansoor, K. N. Furuya, "Pediatric nonalcoholic fatty liver disease, " Current Gastroenterology Reports, vol. 18, no. 5, article 24, 2016.
3. Z. M. Younossi, A. B. Koenig, D. Abdelatif, Y. Fazel, L. Henry, M. Wymer, "Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, outcomes, " Hepatology, vol. 64, no. 1, pp. 73-84, 2016.
4. K. Bettermann, T. Hohensee, J. Haybaeck, "Steatosis and steatohepatitis: complex disorders, " International Journal of Molecular Sciences, vol. 15, no. 6, pp. 9924-9944, 2014.
5. G. Baffy, "Kupffer cells in non-alcoholic fatty liver disease: the emerging view, " Journal ofHepatology, vol. 51, no. 1, pp. 212-223, 2009.
6. N. S. Betrapally, P. M. Gillevet, J. S. Bajaj, "Changes in the intestinal microbiome and alcoholic and nonalcoholic liver diseases: causes or effects" Gastroenterology, vol. 150, no. 8, pp. 1745-1755. e3, 2016.
7. A. Feldman, S. K. Eder, T. K. Felder et al., "Clinical and metabolic characterization of lean caucasian subjects with nonalcoholic fatty liver, "The American Journal of Gastroenterology, 2016.
8. B. Vos, C. Moreno, N. Nagy et al., "Lean non-alcoholic fatty liver disease (Lean-NAFLD): a major cause of cryptogenic liver disease, " ActaGastro-Enterologica Belgica, vol. 74, no. 3, pp. 389-394, 2011.
9. R.-N. Feng, S.-S. Du, C. Wang et al., "Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population, "World Journal of Gastroenterology, vol. 20, no. 47, pp. 17932-17940, 2014.
10. J. Ludwig, T. R. Viggiano, D. B. McGill, B. J. Oh, "Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease, " Mayo Clinic Proceedings, vol. 55, no. 7, pp. 434-438, 1980.
11. N. Chalasani, Z. Younossi, J. E. Lavine et al., "The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, AmericanCollege of Gastroenterology, the American GastroenterologicalAssociation, " Hepatology, vol. 55, no. 6, pp. 2005-2023, 2012.
12. H. Wobser, C. Dorn, T. S. Weiss et al., "Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells, " Cell Research, vol. 19, no. 8, pp. 996-1005, 2009.
13. C. Brenner, L. Galluzzi, O. Kepp, G. Kroemer, "Decoding cell death signals in liver inflammation, " Journal of Hepatology, vol. 59, no. 3, pp. 583-594, 2013.
14. D. M. Lebensztejn, M. Flisiak-Jackiewicz, I. Biaokoz-Kalinowska, A. Bobrus-Chociej, I. Kowalska, "Hepatokines and non-alcoholic fatty liver disease, " Acta Biochimica Polonica, vol. 63, no. 3, pp. 459-467, 2016.
15. M. Ganz and G. Szabo, "Immune and inflammatory pathways in NASH, " Hepatology International, vol. 7, no. S2, pp. 771-781, 2013.
16. S. McPherson, T. Hardy, E. Henderson, A. D. Burt, C. P. Day, Q. M. Anstee, "Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management, " Journal of Hepatology, vol. 62, no. 5, pp. 1148-1155, 2015.
17. C. P. Day and O. F. W. James, "Hepatic steatosis: innocent bystander or guilty party" Hepatology, vol. 27, no. 6, pp. 1463-1466, 1998.
18. Y.-T. Zhan and W. An, "Roles of liver innate immune cells in nonalcoholic fatty liver disease, "World Journal of Gastroenterology, vol. 16, no. 37, pp. 4652-4660, 2010.
19. C. P. Day and O. F. W. James, "Steatohepatitis: a tale of two 'Hits'" Gastroenterology, vol. 114, no. 41, pp. 842-845, 1998.
20. W. Peverill, L. W. Powell, R. Skoien, "Evolving concepts in the pathogenesis ofNASH: beyond steatosis and inflammation, " International Journal of Molecular Sciences, vol. 15, no. 5, pp. 8591-8638, 2014.
21. S. L. Friedman, "Liver fibrosis in 2012: convergent pathways that cause hepatic fibrosis in NASH, " Nature Reviews Gastroenterology & Hepatology, vol. 10, no. 2, pp. 71-72, 2013.
22. H. Tilg and A. R. Moschen, "Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis, " Hepatology, vol. 52, no. 5, pp. 1836-1846, 2010.
23. S. Romeo, J. Kozlitina, C. Xing et al., "Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease, " Nature Genetics, vol. 40, no. 12, pp. 1461-1465, 2008.
24. N. Chalasani, X. Guo, R. Loomba et al., "Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease, " Gastroenterology, vol. 139, no. 5, pp. 1567. e6-1576. e6, 2010.
25. E. K. Speliotes, L. M. Yerges-Armstrong, J. Wu et al., "Genomewide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits, " PLoS Genetics, vol. 7, no. 3, article e1001324, 2011.
26. Y. Rotman, C. Koh, J. M. Zmuda, D. E. Kleiner, T. J. Liang, "The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease, " Hepatology, vol. 52, no. 3, pp. 894-903, 2010.
27. R. Xu, A. Tao, S. Zhang, Y. Deng, G. Chen, "Association between patatin-like phospholipase domain containing 3 gene (PNPLA3) polymorphisms and nonalcoholic fatty liver disease: a HuGE review and meta-analysis, " Scientific Reports, vol. 5, article 9284, 2015.
28. N. Santoro, R. Kursawe, E. D'Adamo et al., "A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents, " Hepatology, vol. 52, no. 4, pp. 1281-1290, 2010.
29. L. Valenti, A. Al-Serri, A. K. Daly et al., "Homozygosity for the patatin-like phospholipase-3/adiponutrin i148m polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease, " Hepatology, vol. 51, no. 4, pp. 1209-1217, 2010.
30. S. He, C. McPhaul, J. Z. Li et al., "A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis, "The Journal of Biological Chemistry, vol. 285, no. 9, pp. 6706-6715, 2010.
31. R. R. Kanherkar, N. Bhatia-Dey, A. B. Csoka, "Epigenetics across the human lifespan, " Frontiers in Cell and Developmental Biology, vol. 2, article 49, 2014.
32. C. Xu, G. Wang, Y. Hao, J. Zhi, L. Zhang, C. Chang, "Correlation analysis between gene expression profile of rat liver tissues and high-fat emulsion-induced nonalcoholic fatty liver, " Digestive Diseases and Sciences, vol. 56, no. 8, pp. 2299-2308, 2011.
33. C. J. Pirola, T. F. Gianotti, A. L. Burgueño et al., "Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease, " Gut, vol. 62, no. 9, pp. 1356-1363, 2013.
34. W. Tian, H. Xu, F. Fang, Q. Chen, Y. Xu, A. Shen, "Brahmarelated gene 1 bridges epigenetic regulation of proinflammatory cytokine production to steatohepatitis inmice, " Hepatology, vol. 58, no. 2, pp. 576-588, 2013.
35. M. D. Hirschey, T. Shimazu, E. Jing et al., "SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome, "Molecular Cell, vol. 44, no. 2, pp. 177-190, 2011.
36. O. Cheung, P. Puri, C. Eicken et al., "Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression, " Hepatology, vol. 48, no. 6, pp. 1810-1820, 2008.
37. N. Nakanishi, Y. Nakagawa, N. Tokushige et al., "The upregulation of microRNA-335 is associatedwith lipid metabolism in liver and white adipose tissue of genetically obese mice, " Biochemical and Biophysical Research Communications, vol. 385, no. 4, pp. 492-496, 2009.
38. I. P. Pogribny, A. Starlard-Davenport, V. P. Tryndyak et al., "Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice, " Laboratory Investigation, vol. 90, no. 10, pp. 1437-1446, 2010.
39. E. M. Brunt, D. E. Kleiner, L. A. Wilson, P. Belt, B. A. Neuschwander-Tetri, NASH Clinical Research Network (CRN), "Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings, " Hepatology, vol. 53, no. 3, pp. 810-820, 2011.
40. Z. Z. Li, M. Berk, T. M. McIntyre, A. E. Feldstein, "Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase, " The Journal of Biological Chemistry, vol. 284, no. 9, pp. 5637-5644, 2009.
41. J. Liu, L. Han, L. Zhu, Y. Yu, "Free fatty acids, not triglycerides, are associated with non-alcoholic liver injury progression in high fat diet induced obese rats, " Lipids in Health and Disease, vol. 15, no. 1, article 27, 2016.
42. M. C. Arkan, A. L. Hevener, F. R. Greten et al., "IKK-links inflammation to obesity-induced insulin resistance, " Nature Medicine, vol. 11, no. 2, pp. 191-198, 2005.
43. X.-H. Li, K. C.-Y. McGrath, S. Nammi, A. K. Heather, B. D. Roufogalis, "Attenuation of liver pro-inflammatory responses by zingiber officinale via inhibition of NF-kappa B activation in high-fat diet-fed rats, " Basic and Clinical Pharmacology and Toxicology, vol. 110, no. 3, pp. 238-244, 2012.
44. M. L. Chaisson, J. T. Brooling, W. Ladiges, S. Tsai, N. Fausto, "Hepatocyte-specific inhibition of NF-B leads to apoptosis after TNF treatment, but not after partial hepatectomy, " The Journal of Clinical Investigation, vol. 110, no. 2, pp. 193-202, 2002.
45. X.-Q. Zhang, C.-F. Xu, C.-H. Yu, W.-X. Chen, Y.-M. Li, "Role of endoplasmic reticulum stress in the pathogenesis of nonalcoholic fatty liver disease, "World Journal of Gastroenterology, vol. 20, no. 7, pp. 1768-1776, 2014.
46. A. D. Lake, P. Novak, R. N. Hardwick et al., "The adaptive endoplasmic reticulum stress response to lipotoxicity in progressive human nonalcoholic fatty liver disease, " Toxicological Sciences, vol. 137, no. 1, Article ID 230, pp. 26-35, 2014.
47. P. J. Meakin, S. Chowdhry, R. S. Sharma et al., "Susceptibility of Nrf2-null mice to steatohepatitis and cirrhosis upon consumption of a high-fat diet is associated with oxidative stress, perturbation of the unfolded protein response, disturbance in the expression of metabolic enzymes but not with insulin resistance, " Molecular and Cellular Biology, vol. 34, no. 17, pp. 3305-3320, 2014.
48. M. Kandel-Kfir, T. Almog, A. Shaish et al., "Interleukin-1 deficiency attenuates endoplasmic reticulum stress-induced liver damage and CHOP expression in mice, " Journal of Hepatology, vol. 63, no. 4, pp. 926-933, 2015.
49. L. Vonghia, P. Michielsen, S. Francque, "Immunological mechanisms in the pathophysiology of non-alcoholic steatohepatitis, " International Journal ofMolecular Sciences, vol. 14, no. 10, pp. 19867-19890, 2013.
50. X. Wan, C. Xu, C. Yu, Y. Li, "Role of NLRP3 inflammasome in the progression of NAFLD to NASH, " Canadian Journal of Gastroenterology and Hepatology, vol. 2016, Article ID 6489012, 7 pages, 2016.
51. V. L. Gadd, R. Skoien, E. E. Powell et al., "The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease, " Hepatology, vol. 59, no. 4, pp. 1393-1405, 2014.
52. V. Bieghs and C. Trautwein, "The innate immune response during liver inflammation and metabolic disease, " Trends in Immunology, vol. 34, no. 9, pp. 446-452, 2013.
53. W. S. Haubrich, "Kupffer of Kupffer cells, " Gastroenterology, vol. 127, no. 1, p. 16, 2004.
54. L. Li and B.-E. Wang, "Kupffer cells and liver fibrosis, " Zhonghua Gan Zang Bing Za Zhi, vol. 15, no. 7, pp. 559-560, 2007.
55. F. Tacke and H. W. Zimmermann, "Macrophage heterogeneity in liver injury and fibrosis, " Journal of Hepatology, vol. 60, no. 5, pp. 1090-1096, 2014.
56. M. Mouzaki, E. M. Comelli, B. M. Arendt et al., "Intestinal microbiota in patients with nonalcoholic fatty liver disease, " Hepatology, vol. 58, no. 1, pp. 120-127, 2013.
57. J. Henao-Mejia, E. Elinav, C. Jin et al., "Inflammasomemediated dysbiosis regulates progression of NAFLD and obesity, " Nature, vol. 482, no. 7384, pp. 179-185, 2012.
58. C. S. Schaffert, M. J. Duryee, C. D. Hunter et al., "Alcohol metabolites and lipopolysaccharide: roles in the development and/or progression of alcoholic liver disease, " World Journal of Gastroenterology, vol. 15, no. 10, pp. 1209-1218, 2009.
59. L. Zhu, S. S. Baker, C. Gill et al., "Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH, " Hepatology, vol. 57, no. 2, pp. 601-609, 2013.
60. V. Bieghs, P. C. N. Rensen, M. H. Hofker, R. Shiri-Sverdlov, "NASH and atherosclerosis are two aspects of a shared disease: central role formacrophages, " Atherosclerosis, vol. 220, no. 2, pp. 287-293, 2012.
61. P. Italiani and D. Boraschi, "From monocytes to M1/M2 macrophages: phenotypical vs. functional differentiation, " Frontiers in Immunology, vol. 5, article 514, 2014.
62. J. Wan, M. Benkdane, F. Teixeira-Clerc et al., "M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease, " Hepatology, vol. 59, no. 1, pp. 130-142, 2014.
63. A. Sica and A. Mantovani, "Macrophage plasticity and polarization: in vivo veritas, " The Journal of Clinical Investigation, vol. 122, no. 3, pp. 787-795, 2012.
64. F. Xiu, M. Catapano, L. Diao, M. Stanojcic, M. G. Jeschke, "Prolonged endoplasmic reticulum-stressed hepatocytes drive an alternative macrophage polarization, " Shock, vol. 44, no. 1, pp. 44-51, 2015.
65. Z. Wenfeng, W. Yakun, M. Di, G. Jianping, W. Chuanxin, H. Chun, "Kupffer cells: increasingly significant role in nonalcoholic fatty liver disease, " Annals of Hepatology, vol. 13, no. 5, pp. 489-495, 2014.
66. A. Eguchi, A. Wree, A. E. Feldstein, "Biomarkers of liver cell death, " Journal of Hepatology, vol. 60, no. 5, pp. 1063-1074, 2014.
67. G. Kolios, V. Valatas, E. Kouroumalis, "Role of Kupffer cells in the pathogenesis of liver disease, " World Journal of Gastroenterology, vol. 12, no. 46, pp. 7413-7420, 2006.
68. W. Huang, A. Metlakunta, N. Dedousis et al., "Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance, " Diabetes, vol. 59, no. 2, pp. 347-357, 2010.
69. T. Sharifnia, J. Antoun, T. G. C. Verriere et al., "Hepatic TLR4 signaling in obese NAFLD, " American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 309, no. 4, pp. G270-G278, 2015.
70. S. M. A. Walenbergh, G. H. Koek, V. Bieghs, R. Shiri-Sverdlov, "Non-alcoholic steatohepatitis: the role of oxidized low-density lipoproteins, " Journal of Hepatology, vol. 58, no. 4, pp. 801-810, 2013.
71. V. Bieghs, F. Verheyen, P. J. van Gorp et al., "Internalization of modified lipids by CD36 and SR-A leads to hepatic inflammation and lysosomal cholesterol storage in Kupffer cells, " PLoS ONE, vol. 7, no. 3, Article ID e34378, 2012.
72. V. Bieghs, P. J. van Gorp, S. M. A. Walenbergh et al., "Specific immunization strategies against oxidized low-density lipoprotein: a novel way to reduce nonalcoholic steatohepatitis in mice, " Hepatology, vol. 56, no. 3, pp. 894-903, 2012.
73. R. Xu, H. Huang, Z. Zhang, F.-S. Wang, "The role of neutrophils in the development of liver diseases, " Cellular & Molecular Immunology, vol. 11, no. 3, pp. 224-231, 2014.
74. S. S. Rensen, Y. Slaats, J. Nijhuis et al., "Increased hepatic myeloperoxidase activity in obese subjects with nonalcoholic steatohepatitis, " The American Journal of Pathology, vol. 175, no. 4, pp. 1473-1482, 2009.
75. N. Alkhouri, G. Morris-Stiff, C. Campbell et al., "Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease, " Liver International, vol. 32, no. 2, pp. 297-302, 2012.
76. R. Ibusuki, H. Uto, S. Arima et al., "Transgenic expression of human neutrophil peptide-1 enhances hepatic fibrosis in mice fed a choline-deficient, L-amino acid-defined diet, " Liver International, vol. 33, no. 10, pp. 1549-1556, 2013.
77. S. Talukdar, D. Y. Oh, G. Bandyopadhyay et al., "Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase, " Nature Medicine, vol. 18, no. 9, pp. 1407-1412, 2012.
78. R. Meli, G. M. Raso, A. Calignano, "Role of innate immune response in non-alcoholic fatty liver disease: metabolic complications and therapeutic tools, " Frontiers in Immunology, vol. 5, article 177, 2014.
79. S. Romagnani, "Type 1 T helper and type 2 T helper cells: functions, regulation and role in protection and disease, " International Journal of Clinical & Laboratory Research, vol. 21, no. 2, pp. 152-158, 1992.
80. H. Sell, C. Habich, J. Eckel, "Adaptive immunity in obesity and insulin resistance, "Nature Reviews Endocrinology, vol. 8, no. 12, pp. 709-716, 2012.
81. E. M. Brunt, "Pathology of nonalcoholic fatty liver disease, " Nature Reviews Gastroenterology & Hepatology, vol. 7, no. 4, pp. 195-203, 2010.
82. J. R. Henning, C. S. Graffeo, A. Rehman et al., "Dendritic cells limit fibroinflammatory injury in nonalcoholic steatohepatitis in mice, " Hepatology, vol. 58, no. 2, pp. 589-602, 2013.
83. Y. Tang, Z. Bian, L. Zhao et al., "Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease, " Clinical and Experimental Immunology, vol. 166, no. 2, pp. 281-290, 2011.
84. I. T. W. Harley, T. E. Stankiewicz, D. A. Giles et al., "IL-17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice, " Hepatology, vol. 59, no. 5, pp. 1830-1839, 2014.
85. M. Rau, A.-K. Schilling, J. Meertens et al., "Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an increased Th17/resting regulatory T cell ratio in peripheral blood and in the liver, "The Journal of Immunology, vol. 196, no. 1, pp. 97-105, 2016.
86. D. A. Winer, S. Winer, M. H. Y. Chng, L. Shen, E. G. Engleman, "B Lymphocytes in obesity-related adipose tissue inflammation and insulin resistance, " Cellular and Molecular Life Sciences, vol. 71, no. 6, pp. 1033-1043, 2014.
87. S. Sutti, A. Jindal, I. Locatelli et al., "Adaptive immune responses triggered by oxidative stress contribute to hepatic inflammation in NASH, " Hepatology, vol. 59, no. 3, pp. 886-897, 2014.
88. E. Albano, E. Mottaran, M. Vidali et al., "Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis, " Gut, vol. 54, no. 7, pp. 987-993, 2005.
89. V. Nobili, M. Parola, A. Alisi et al., "Oxidative stress parameters in paediatric non-alcoholic fatty liver disease, " International Journal of Molecular Medicine, vol. 26, no. 4, pp. 471-476, 2010.
90. D. A. Winer, S. Winer, L. Shen et al., "B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies, " Nature Medicine, vol. 17, no. 5, pp. 610-617, 2011.
91. L. G. Ng, A. P. R. Sutherland, R. Newton et al., "B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells, " Journal of Immunology, vol. 173, no. 2, pp. 807-817, 2004.
92. K. Kawasaki, M. Abe, F. Tada et al., "Blockade of B-cellactivating factor signaling enhances hepatic steatosis induced by a high-fat diet and improves insulin sensitivity, " Laboratory Investigation, vol. 93, no. 3, pp. 311-321, 2013.
93. D.-H. Kim and M.-S. Do, "BAFF knockout improves systemic inflammation via regulating adipose tissue distribution in highfat diet-induced obesity, " Experimental & Molecular Medicine, vol. 47, article e129, 2015.
94. J. Bhattacharjee, J. M. Kumar, S. Arindkar et al., "Role of immunodeficient animalmodels in the development of fructose induced NAFLD, " Journal of Nutritional Biochemistry, vol. 25, no. 2, pp. 219-226, 2014.
95. G. Szabo and T. Csak, "Inflammasomes in liver diseases, " Journal of Hepatology, vol. 57, no. 3, pp. 642-654, 2012.
96. T. Csak, M. Ganz, J. Pespisa, K. Kodys, A. Dolganiuc, G. Szabo, "Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells, " Hepatology, vol. 54, no. 1, pp. 133-144, 2011.
97. A. Wree, M. D. McGeough, C. A. Peña et al., "NLRP3 inflammasomeactivation is required for fibrosis development inNAFLD, " Journal of Molecular Medicine, vol. 92, no. 10, pp. 1069-1082, 2014.
98. Y. Kamari, A. Shaish, E. Vax et al., "Lack of interleukin-1 or interleukin-1 inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice, " Journal of Hepatology, vol. 55, no. 5, pp. 1086-1094, 2011.
99. L. J. Dixon, M. Berk, S. Thapaliya, B. G. Papouchado, A. E. Feldstein, "Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis, " Laboratory Investigation, vol. 92, no. 5, pp. 713-723, 2012.
100. R. Bataller and D. A. Brenner, "Liver fibrosis, " The Journal of Clinical Investigation, vol. 115, no. 2, pp. 209-218, 2005.
101. N. Kawada, "Cytoglobin as a marker of hepatic stellate cellderived myofibroblasts, " Frontiers in Physiology, vol. 6, article 329, 2015.
102. R. Safadi and S. L. Friedman, "Hepatic fibrosis-role of hepatic stellate cell activation, " Medscape GeneralMedicine, vol. 4, no. 3, article 27, 2002.
103. G. Ramadori and B. Saile, "Portal tract fibrogenesis in the liver, " Laboratory Investigation, vol. 84, no. 2, pp. 153-159, 2004.
104. A. M. Gressner and R. Weiskirchen, "Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-as major players and therapeutic targets, " Journal of Cellular and Molecular Medicine, vol. 10, no. 1, pp. 76-99, 2006.
105. R. K. Moreira, "Hepatic stellate cells and liver fibrosis, " Archives of Pathology and Laboratory Medicine, vol. 131, no. 11, pp. 1728-1734, 2007.
106. R. Weiskirchen and F. Tacke, "Cellular and molecular functions of hepatic stellate cells in inflammatory responses and liver immunology, " Hepatobiliary Surgery and Nutrition, vol. 3, no. 6, pp. 344-363, 2014.
107. M. Thapa, R. Chinnadurai, V. M. Velazquez et al., "Liver fibrosis occurs through dysregulation of MyD88-dependent innate Bcell activity, " Hepatology, vol. 61, no. 6, pp. 2067-2079, 2015.
108. P. Kocabayoglu and S. L. Friedman, "Cellular basis of hepatic fibrosis and its role in inflammation and cancer, " Frontiers in Bioscience-Scholar, vol. 5, no. 1, pp. 217-230, 2013.
109. K. Uchio, B. Tuchweber, N. Manabe, G. Gabbiani, J. Rosenbaum, A. Desmoulière, "Cellular retinol-binding protein-1 expression andmodulation during in vivo and in vitromyofibroblastic differentiation of rat hepatic stellate cells and portal fibroblasts, " Laboratory Investigation, vol. 82, no. 5, pp. 619-628, 2002.
110. H. Motoyama, T. Komiya, L. T. T. Thuy et al., "Cytoglobin is expressed in hepatic stellate cells, but not in myofibroblasts, in normal and fibrotic human liver, " Laboratory Investigation, vol. 94, no. 2, pp. 192-207, 2014.
111. D. Kobold, A. Grundmann, F. Piscaglia et al., "Expression of reelin in hepatic stellate cells and during hepatic tissue repair: a novel marker for the differentiation of HSC from other liver myofibroblasts, " Journal of Hepatology, vol. 36, no. 5, pp. 607-613, 2002.
112. J. A. Dranoff, E. A. Kruglov, S. C. Robson, N. Braun, H. Zimmermann, J. Svigny, "The ecto-nucleoside triphosphate diphosphohydrolase NTPDase2/CD39l1 is expressed in a novel functional compartment within the liver, " Hepatology, vol. 36, no. 5, pp. 1135-1144, 2002.
113. G. O. Elpek, "Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: an update, " World Journal of Gastroenterology, vol. 20, no. 23, pp. 7260-7276, 2014.
114. U. E. Lee and S. L. Friedman, "Mechanisms of hepatic fibrogenesis, " Best Practice& Research: Clinical Gastroenterology, vol. 25, no. 2, pp. 195-206, 2011.
115. J. Wanninger, M. Neumeier, C. Hellerbrand et al., "Lipid accumulation impairs adiponectin-mediated induction of activin A by increasing TGFbeta in primary human hepatocytes, " Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids, vol. 1811, no. 10, pp. 626-633, 2011.
116. R. Bansal, J. van Baarlen, G. Storm, J. Prakash, "The interplay of the Notch signaling in hepatic stellate cells and macrophages determines the fate of liver fibrogenesis, " Scientific Reports, vol. 5, Article ID18272, 2015.
117. B. Schnabl, C. A. Bradham, B. L. Bennett, A. M. Manning, B. Stefanovic, D. A. Brenner, "TAK1/JNK and p38 have opposite effects on rat hepatic stellate cells, " Hepatology, vol. 34, no. 5, pp. 953-963, 2001.
118. L. A. Borthwick and D. A. Mann, "Liver: osteopontin and HMGB1: novel regulators of HSC activation, " Nature Reviews Gastroenterology & Hepatology, vol. 13, no. 6, pp. 320-322, 2016.
119. C. D. Guy, A. Suzuki, M. Zdanowicz et al., "Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease, " Hepatology, vol. 55, no. 6, pp. 1711-1721, 2012.
120. A. Dajani and A. AbuHammour, "Treatment of nonalcoholic fatty liver disease: where do we stand An overview, " Saudi Journal of Gastroenterology, vol. 22, no. 2, pp. 91-105, 2016.
121. M. C. Cave, H. B. Clair, J. E. Hardesty et al., "Nuclear receptors and nonalcoholic fatty liver disease, " Biochimica et Biophysica Acta, vol. 1859, no. 9, pp. 1083-1099, 2016.
122. J. A. Lpez-Velzquez, L. D. Carrillo-Crdova, N. C. Chvez-Tapia, M. Uribe, N. Mndez-Snchez, "Nuclear receptors in nonalcoholic fatty liver disease, " Journal of Lipids, vol. 2012, Article ID 139875, 10 pages, 2012.
123. A. C. Li and C. K. Glass, "The macrophage foam cell as a target for therapeutic intervention, " Nature Medicine, vol. 8, no. 11, pp. 1235-1242, 2002.
124. J. K. Dowman, J. W. Tomlinson, P. N. Newsome, "Pathogenesis of non-alcoholic fatty liver disease, " Quarterly Journal of Medicine, vol. 103, no. 2, pp. 71-83, 2009.
125. A. J. Sanyal, N. Chalasani, K. V. Kowdley et al., "Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis, "The New England Journal of Medicine, vol. 362, no. 18, pp. 1675-1685, 2010.
126. C. D. Guy, A. Suzuki, M. F. Abdelmalek, J. L. Burchette, A. M. Diehl, "Treatment response in the PIVENS trial is associated with decreased hedgehog pathway activity, " Hepatology, vol. 61, no. 1, pp. 98-107, 2015.
127. P. Hirsova and G. J. Gores, "Ballooned hepatocytes, undead cells, sonic hedgehog, vitamin E: therapeutic implications for nonalcoholic steatohepatitis, " Hepatology, vol. 61, no. 1, pp. 15-17, 2015.
128. Y. Liu, R. Wei, T.-P. Hong, "Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease, " World Journal of Gastroenterology, vol. 20, no. 27, pp. 9090-9097, 2014.
129. J. K. Dyson, Q. M. Anstee, S. McPherson, "Non-alcoholic fatty liver disease: a practical approach to treatment, " Frontline Gastroenterology, vol. 5, no. 4, pp. 277-286, 2014.
130. L. Eslami, S. Merat, S. Nasseri-Moghaddam, "Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD): a systematic review, " Middle East Journal of Digestive Diseases, vol. 1, no. 2, pp. 89-99, 2009.